News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
131,637 Results
Type
Article (8884)
Company Profile (34)
Press Release (122719)
Multimedia
Podcasts (7)
Webinars (2)
Section
Business (38821)
Career Advice (331)
Deals (5712)
Drug Delivery (11)
Drug Development (11755)
Employer Resources (17)
FDA (3354)
Job Trends (3539)
News (62100)
Policy (6467)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
Academia (970)
Academic (1)
Accelerated approval (2)
Adcomms (2)
Allergies (22)
Alliances (12710)
ALS (21)
Alzheimer's disease (310)
Antibody-drug conjugate (ADC) (46)
Approvals (3487)
Artificial intelligence (103)
Autoimmune disease (14)
Automation (21)
Bankruptcy (40)
Best Places to Work (2738)
BIOSECURE Act (3)
Biosimilars (17)
Biotechnology (23)
Bladder cancer (40)
Brain cancer (9)
Breast cancer (139)
Cancer (945)
Cardiovascular disease (44)
Career advice (296)
Career pathing (6)
CAR-T (42)
CDC (7)
Celiac Disease (1)
Cell therapy (109)
Cervical cancer (11)
Clinical research (9560)
Collaboration (415)
Company closure (1)
Compensation (13)
Complete response letters (7)
COVID-19 (802)
CRISPR (28)
C-suite (137)
Cystic fibrosis (13)
Data (1011)
Decentralized trials (1)
Denatured (5)
Depression (9)
Diabetes (47)
Diagnostics (3521)
Digital health (4)
Diversity (1)
Diversity, equity & inclusion (6)
Drug discovery (68)
Drug pricing (15)
Drug shortages (2)
Duchenne muscular dystrophy (46)
Earnings (10901)
Editorial (6)
Employer branding (3)
Employer resources (15)
Events (14037)
Executive appointments (184)
FDA (3859)
Fibrodysplasia Ossificans Progressiva (2)
Frontotemporal dementia (3)
Funding (264)
Gene editing (40)
Generative AI (10)
Gene therapy (96)
GLP-1 (139)
Government (1191)
Grass and pollen (3)
Guidances (56)
Healthcare (2893)
HIV (12)
Huntington's disease (3)
IgA nephropathy (3)
Immunology and inflammation (18)
Immuno-oncology (7)
Indications (22)
Infectious disease (888)
Inflammatory bowel disease (17)
Influenza (52)
Intellectual property (29)
Interviews (56)
IPO (1819)
IRA (3)
Job creations (921)
Job search strategy (253)
JPM (12)
Kidney cancer (1)
Labor market (8)
Layoffs (52)
Leadership (7)
Legal (1273)
Liver cancer (14)
Longevity (1)
Lung cancer (138)
Lymphoma (95)
Machine learning (9)
Management (3)
Manufacturing (181)
MASH (9)
Medical device (1889)
Medtech (1891)
Mergers & acquisitions (4055)
Metabolic disorders (101)
Multiple sclerosis (16)
NASH (1)
Neurodegenerative disease (53)
Neuropsychiatric disorders (5)
Neuroscience (444)
NextGen: Class of 2026 (1027)
Non-profit (869)
Now hiring (14)
Obesity (44)
Opinion (36)
Ovarian cancer (20)
Pain (19)
Pancreatic cancer (27)
Parkinson's disease (32)
Partnered (10)
Patents (53)
Patient recruitment (34)
Peanut (11)
People (12698)
Pharmaceutical (8)
Pharmacy benefit managers (1)
Phase 1 (2856)
Phase 2 (3818)
Phase 3 (3592)
Pipeline (832)
Policy (29)
Postmarket research (444)
Preclinical (1577)
Press Release (37)
Prostate cancer (39)
Psychedelics (2)
Radiopharmaceuticals (43)
Rare diseases (115)
Real estate (2249)
Recruiting (6)
Regulatory (4755)
Reports (9)
Research institute (946)
Resumes & cover letters (41)
Rett syndrome (3)
RNA editing (1)
RSV (17)
Schizophrenia (10)
Series A (38)
Series B (23)
Service/supplier (1)
Sickle cell disease (12)
Special edition (2)
Spinal muscular atrophy (47)
Sponsored (7)
Startups (859)
State (1)
Stomach cancer (2)
Supply chain (25)
Tariffs (6)
The Weekly (2)
Vaccines (188)
Venture capital (8)
Weight loss (21)
Women's health (24)
Date
Today (18)
Last 7 days (79)
Last 30 days (298)
Last 365 days (4308)
2026 (401)
2025 (4426)
2024 (5715)
2023 (6732)
2022 (10539)
2021 (11026)
2020 (10826)
2019 (7984)
2018 (6300)
2017 (6710)
2016 (6697)
2015 (7469)
2014 (5860)
2013 (5088)
2012 (5324)
2011 (5476)
2010 (4898)
Location
Africa (165)
Alabama (14)
Alaska (2)
Arizona (51)
Arkansas (2)
Asia (8516)
Australia (1366)
California (1449)
Canada (488)
China (101)
Colorado (74)
Connecticut (99)
Delaware (58)
Europe (17433)
Florida (193)
Georgia (95)
Hawaii (1)
Idaho (7)
Illinois (100)
India (8)
Indiana (78)
Iowa (2)
Japan (142)
Kansas (33)
Kentucky (7)
Louisiana (4)
Maine (27)
Maryland (190)
Massachusetts (1021)
Michigan (94)
Minnesota (103)
Mississippi (2)
Missouri (74)
Montana (10)
Nebraska (3)
Nevada (8)
New Hampshire (9)
New Jersey (641)
New Mexico (9)
New York (518)
North Carolina (247)
North Dakota (2)
Northern California (604)
Ohio (76)
Oklahoma (4)
Oregon (6)
Pennsylvania (261)
Puerto Rico (1)
Rhode Island (14)
South America (220)
South Carolina (7)
Southern California (621)
Tennessee (36)
Texas (369)
United States (6081)
Utah (78)
Vermont (1)
Virginia (36)
Washington D.C. (11)
Washington State (143)
West Virginia (1)
Wisconsin (28)
131,637 Results for "shin nippon biomedical laboratories".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Policy
Satsuma Fails to Secure FDA Approval for Nasal Powder Migraine Drug
The FDA’s Complete Response Letter identified problems with the drug candidate’s chemistry, manufacturing and controls, parent company Shin Nippon Biomedical Laboratories announced Thursday.
January 18, 2024
·
2 min read
·
Tristan Manalac
Drug Development
Satsuma Pharmaceuticals and SNBL Announce Five Abstracts on STS101 for the Acute Treatment of Migraine to be Presented at the American Headache Society’s 66th Annual Scientific Meeting
Satsuma Pharmaceuticals, Inc. and its corporate parent, Shin Nippon Biomedical Laboratories, Ltd., announced that five abstracts describing efficacy and safety results from the STS101 Phase 3 clinical study program were selected for presentation at the American Headache Society’s 66th Annual Scientific Meeting.
June 13, 2024
·
6 min read
Business
MiNA Therapeutics Enters Research Collaboration with Nippon Shinyaku to Develop RNAa Therapeutics Targeting Rare Neurodegenerative Diseases
MiNA Therapeutics today announced a research collaboration and licensing agreement option with Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; Headquarters: Kyoto; President: Toru Nakai), an innovation-driven Japanese-based pharmaceutical company focused on disease areas of high unmet medical need.
April 4, 2024
·
3 min read
Press Releases
Amaran Biotech Signs MOU with Nippon Fine Chemical
March 7, 2025
·
3 min read
Press Releases
Nippon Shokubai Plans to Expand Its GMP-compliant Nucleic Acid Drug API Manufacturing Capacity Tenfold
June 24, 2025
·
2 min read
Press Releases
The Jackson Laboratory acquires New York Stem Cell Foundation to transform biomedical research and accelerate precision therapies for patients
October 21, 2025
·
4 min read
Gene therapy
Regenxbio Jumps on Potential $800M Rare Disease Deal With Nippon Shinyaku
In exchange for its investigational gene therapies, Regenxbio will receive $110 million upfront and up to $700 million in milestones. After hitting an all-time low of $6.95 at close of business yesterday, the stock surged on the news by nearly 20% before markets opened Tuesday.
January 14, 2025
·
2 min read
·
Tristan Manalac
Business
epitoMAP Inc., Animal Allergy Clinical Laboratories Inc. and Nippon Zenyaku Kogyo Co., Ltd. Enter into License Agreement
epitoMAP Inc. and Animal Allergy Clinical Laboratories Inc. entered into a License Agreement for an antibody pharmaceutical for veterinary use, CRE-DR-B, with Nippon Zenyaku Kogyo Co., Ltd. on November 10, 2023.
November 17, 2023
·
2 min read
Press Releases
Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform
January 6, 2026
·
2 min read
Vicore and Nippon Shinyaku Enter into an Exclusive License Agreement to Develop and Commercialize C21 in Japan
Vicore Pharma Holding AB, unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists, announced it has entered into an exclusive licensing agreement with Nippon Shinyaku Co. Ltd., a leading Japanese pharmaceutical company, to develop and commercialize Vicore’s drug candidate C21 in Japan.
February 9, 2024
·
4 min read
1 of 13,164
Next